{"product_id":"glp-2t-nasal","title":"GLP-2T Nasal Spray","description":"\u003ch3\u003eGLP-2T — nasal spray format\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e15mL Nasal Spray\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThis listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.\u003c\/p\u003e\u003cp\u003eBecause this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized GLP-2T vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.\u003c\/p\u003e\u003ch3\u003eTechnical overview\u003c\/h3\u003e\u003cp\u003e\u003cem\u003edual incretin receptor agonist peptide\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eGLP-2T is a long-acting peptide engineered to activate both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Large clinical trials have studied once-weekly GLP-2T in metabolic endpoints including glycemic measures, body weight, cardiometabolic markers, and comparative incretin pharmacology.\u003c\/p\u003e\u003cp\u003eGLP-2T has FDA-approved counterparts, including Mounjaro and Zepbound, for their specific approved uses and labeled formulations. Research-grade GLP-2T powder is not Mounjaro or Zepbound, is not an approved drug product, is Research Use Only, and is not for human consumption. Reported ranges below describe published trial dose arms or approved-product contexts, not recommendations.\u003c\/p\u003e\u003ch3\u003eMechanism of action\u003c\/h3\u003e\u003cp\u003eGLP-2T activates GIP and GLP-1 receptors, linking two incretin pathways that influence insulin secretion, glucagon dynamics, gastric emptying, appetite-related signaling, and energy-balance endpoints. Its fatty-acid modification supports prolonged albumin binding and once-weekly exposure in approved-product studies. Research comparisons often evaluate whether dual incretin signaling produces different metabolic and tolerability profiles than selective GLP-1 receptor agonism.\u003c\/p\u003e\u003ch3\u003eResearch applications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eincretin biology\u003c\/li\u003e\n\u003cli\u003eGIP receptor signaling\u003c\/li\u003e\n\u003cli\u003eGLP-1 receptor signaling\u003c\/li\u003e\n\u003cli\u003emetabolic pharmacology\u003c\/li\u003e\n\u003cli\u003ebody weight and glycemic endpoints\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eFields of active investigation, not claims. Investigation is not proof.\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003eGLP-2T is studied by endocrinologists, obesity researchers, cardiometabolic trialists, pharmacokinetic modelers, and regulatory scientists. Quality and formulation specialists distinguish regulated finished products from research-grade materials because they are not interchangeable.\u003c\/p\u003e\u003ch3\u003eAmounts reported in the literature\u003c\/h3\u003e\u003cp\u003eWhat published research and laboratory protocols document. These describe what was \u003cem\u003estudied\u003c\/em\u003e — they are not instructions, recommendations, or a protocol for use.\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eReported amount\u003c\/th\u003e\n\u003cth\u003eFrequency\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eResearch context\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e5 mg – 15 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly in trial protocols\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSURPASS clinical trial dose arms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5 mg – 15 mg\u003c\/td\u003e\n\u003ctd\u003eonce weekly in trial protocols\u003c\/td\u003e\n\u003ctd\u003esubcutaneous\u003c\/td\u003e\n\u003ctd\u003eSURMOUNT obesity trial dose arms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eHandling and storage\u003c\/h3\u003e\u003cp\u003eApproved GLP-2T products have label-specific refrigerated storage instructions; research-grade lyophilized material is typically stored frozen or refrigerated per supplier specifications and protected from moisture and light.\u003c\/p\u003e\u003ch3\u003eNotes on combined research\u003c\/h3\u003e\u003cp\u003eGLP-2T is often compared with GLP-1 receptor agonists, but combining incretin compounds or layering metabolic agents can confound appetite, glucose, gastrointestinal, and body-weight endpoints. Research-grade GLP-2T should never be positioned as a substitute for Mounjaro or Zepbound.\u003c\/p\u003e\u003ch3\u003eAnalytical specifications\u003c\/h3\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e≥99.0% by HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormat\u003c\/th\u003e\n\u003ctd\u003e15mL Nasal Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePhysical form\u003c\/th\u003e\n\u003ctd\u003eSee product format\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eThird-party laboratory\u003c\/th\u003e\n\u003ctd\u003eAxisPharm, LLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLots with COA on file\u003c\/th\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlso referred to as\u003c\/th\u003e\n\u003ctd\u003eLY3298176, dual GIP\/GLP-1 receptor agonist, GIP\/GLP-1 agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReported half-life\u003c\/th\u003e\n\u003ctd\u003eApproximately 5 days is commonly cited for GLP-2T in clinical pharmacology and labeling contexts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003cp\u003eIdentity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.\u003c\/p\u003e\u003ch3\u003eFrequently asked questions\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003ewhat is the dosage for GLP-2T\u003c\/strong\u003e\u003cbr\u003ePublished trials commonly studied 5, 10, and 15 mg once weekly dose arms. Those data describe clinical trial or approved-product contexts, not research-grade material use.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow much bacteriostatic water for GLP-2T\u003c\/strong\u003e\u003cbr\u003eResearch reconstitution volumes often use 1-3 mL depending on vial strength and target concentration. This is concentration math only.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-2T dosage per day\u003c\/strong\u003e\u003cbr\u003eThe major clinical literature uses once-weekly exposure, not daily dosing. Research-grade GLP-2T is RUO and not for human consumption.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-2T dosage chart\u003c\/strong\u003e\u003cbr\u003eA chart should distinguish trial dose arms, approved product titration, and lab concentration examples. These should not be blended.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ehow long does GLP-2T take\u003c\/strong\u003e\u003cbr\u003eTrials evaluate metabolic endpoints over weeks to months, while pharmacokinetic steady state depends on its multi-day half-life.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eGLP-2T half life\u003c\/strong\u003e\u003cbr\u003eGLP-2T is commonly cited with an approximate 5-day half-life, supporting once-weekly dosing in approved-product studies.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003ecan GLP-2T be stacked\u003c\/strong\u003e\u003cbr\u003eCombination metabolic research requires careful controls and medical-regulatory distinction. RUO GLP-2T is not Mounjaro or Zepbound.\u003c\/p\u003e\u003ch3\u003eReferences\u003c\/h3\u003e\u003cp\u003eEvery reference below resolves to an indexed paper. We would rather cite less and cite accurately.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34170647\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eGLP-2T versus GLP-1 S Once Weekly in Patients with Type 2 Diabetes.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eGLP-2T Once Weekly for the Treatment of Obesity.\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35133415\/\" target=\"_blank\" rel=\"noopener nofollow\"\u003eEffect of Subcutaneous GLP-2T vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eResearch use only\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eFor laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications.\u003c\/strong\u003e This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.\u003c\/p\u003e","brand":"US Peptide Labs","offers":[{"title":"40mg","offer_id":44076218548311,"sku":"CW\/P-TIR40N","price":220.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/2721\/3143\/files\/glp-2t-nasal-40mg.png?v=1790198568","url":"https:\/\/uspeptidelabs.co\/products\/glp-2t-nasal","provider":"US Peptide Labs | High Quality American-made","version":"1.0","type":"link"}